FDA Brief

Warning letters Drugs

FDA warning letter to

New Green Nutrition Inc.

High riskIssued Oct 26Posted Nov 3Center for Drug Evaluation and Research (CDER)

FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

What happened

In September 2026, FDA reviewed New Green Nutrition’s website and obtained a sample of “Qu Feng Huo Luo Dan” through the site. Laboratory analysis confirmed the product contains dexamethasone, a steroid not declared on the label. FDA also found disease-treatment claims for four products, making them unapproved new drugs.

What FDA found

  1. The website and packaging label four products for treating diseases, so FDA treats them as drugs.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  2. FDA says the four products are unapproved new drugs because no FDA-approved application is in effect for them.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
  3. Qu Feng Huo Luo Dan is misbranded because its label does not disclose dexamethasone, which FDA lab analysis found in the product.

    FD&C Act section 502(a), 21 U.S.C. 352(a)

What FDA wants

FDA tells the company to respond within 15 business days to FDAAdvisory@fda.hhs.gov with the corrective steps taken, steps to prevent recurrence, and related documents, and to include reference number 737576 in the subject line.

Who should pay attention

  • retailers and online marketplaces selling imported herbal products
  • consumers using arthritis, pain, or eye products
  • brands that depend on accurate ingredient labels

This is a summary. Read the original letter on fda.gov.

New Green Nutrition Inc.'s FDA history

  1. New Green Nutrition, Inc.

    Finished Pharmaceuticals/Unapproved New Drug/Misbranded

Full company page

Similar letters to other companies

  1. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  2. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk